Website Reviews SmartLiving123

June 14, 2010

www.dendreon.com | Dendreon Corporation | Prostate Cancer Therapy: Provenge

Filed under: Health & Medicine — Tags: , , , , — Paul @ 2:07 pm

www.dendreon.com | Dendreon Corporation | Prostate Cancer Therapy: Provenge

www.dendreon.com is the website for Dendreon Corporation, a US biotechnology company headquartered in Seattle, WA. Dendreon Corporation aims to find therapeutic treatments for different types of cancer and they want to provide quick and easy help to cancer patients all over the world. Their motto is “Targeting cancer, transforming lives”.

www.dendreon.com gives a large amount of information about every detail of the company. At this site, you can learn about Dendreon’s mission, their values, commitment to patients, find out who the executives of the company are, and their contact information.

If you are want to know cancer treatment products developed by Dendreon, you can visit their products section, where you can look over how these cancer treatment products are manufactured and what they can do. For instance, you can find the detailed describing information about PROVENGE, a new FDA approved prostate cancer therapy, including the safety information associated with this Provenge prostate cancer therapy. So prostate cancer patients who want to learn how provenge works will find dendreon.com informative.

If you are an investor and interested in purchasing Dendreon Corporation stock (their stock symbol is DNDN), you may be interested in Dendreon’s current research and development projects and the various news and events taking place atDendreon. All this information and more are available on their website. In the section specifically designed for investors and for the press, you can find out the latest about what’s going on at the Dendreon Corporation, and view their webcasts as well.

dendreon.com also has a cancer patients resources section, where you can find cancer patient’s information and clinical trials. It gives the success stories of those cancer patients who overcame cancer and are living happily, which makes www.dendreon.com a source of inspiration for cancer patients.

If you want to pursue a career at Dendreon Corporation, you may want to pay a visit to their career section. This section is for people seeking Dendreon jobs and career opportunities. You can view the open dendreon jobs and apply for dendreon jobs online.

In conclusion, there is a lot to learn from visiting www.dendreon.com. This website provides information for people who want to invest in DNDN, work at Dendreon, fight against cancer, find updated information on about new improvements in cancer treatment. If you are fighting cancer or you want to help others to fight cancer, visit www.dendreon.com to find more information.

www.dendreon.com – Prostate Cancer Treatment – Mechanism of Provenge Vaccine

Filed under: Health & Medicine — Tags: , , , , — Paul @ 4:03 am

Prostate Cancer New Treatment Option: Dendreon Provenge Vaccine – www.dendreon.com

Provenge Vaccine is new treatment option for  prostate cancer approved by the US Food and Drug Administration (FDA) on April 29, 2010. Provenge vaccine (sipuleucel-T) was researched and developed by Dendreon Corporation, a biotechnology company specializing in developing therapeutic cancer treatments. Dendreon Corporation is a US-based biotech company, physically located in Seattle, Washington. You can find detailed information of Dendreon corporation background, products and ongoing research projects at www.dendreon.com, their official website.

The mechanism of Provenge
Provenge is designed to stimulate patients’ own immune system and increase their function in getting rid of cancerous prostate cells. How does Provenge work? Provenge is a vaccine which helps the patients’ immune system to recognize the prostate cancer cells better. It works by providing more prostatic acid phosphatase (PAP) activated antigen presenting cells (APCs). PAP is a prostate cancer cell specific protein, which doesn’t exist on normal prostate cells.

How to produce Provenge Vaccine products
In order to produce the Provenge vaccine, doctors will take patients’ peripheral blood mononuclear cells by a standard procedure called Leukapheresis,and co-culture the blood cells with recombinant human proteins, specifically the protein PAP-GM-CSF. After several days of in vitro culture, autologous peripheral blood mononuclear cells, the active component of the Provenge product, will be produced. GM-CSF stands for granulocyte macrophage colony stimulating factor which can help to activate the immune cells. The autologous peripheral blood mononuclear cells contain a large amount of PAP-activated APCs, which plays a major role in stimulating the patients’ immune system. Because of the nature of the production procedure, and due to the fact that this is a biological process with intrinsic variability depending on the viability of the patient’s own APCs, the quality of the final vaccine product is not 100% predictable, and batch to batch variation with even a single patient may occur. (See Provenge Full Prescribing Information for details. You can download it at Dendreon.com).
Not all the prostate cancer patients can be treated with Provenge Vaccine.
Dendreon Provenge Vaccine is a new prostate cancer cure but it is not an option for all prostate cancer patients. Provenge Vaccine products are only suitable for treating asymptomatic or minimally symptomatic metastatic, and castrate resistant prostate cancer. Provenge vaccine prostate cancer treatment may also be complicated by other conditions such as chemotherapy and application of immunosuppressive agents. If you want to learn more on Prostate Cancer New Treatment Option: Dendreon Provenge Vaccine, you should visit www.dendreon.com, the Dendreon Corporation website or consult your doctor for details.

Resources:

Provenge Full Prescribing Information from www.dendreon.com

June 13, 2010

nlbreastcancersettlement.ca – Newfoundland Breast Cancer Lawsuit Settlement

Filed under: Legal — Tags: , , , , — Paul @ 1:22 pm

How to Get a Newfoundland & Labrador Breast Cancer Class Action Lawsuit Settlement Claim Form | www.nlbreastcancersettlement.ca

Between 1997 and 2005, the Newfoundland and Labrador Eastern Health Authority of Canada reported erroneous test results to breast cancer patients, and subsequently failed to report the full scope of the error when it was discovered. Following a scathing press report by the Canadian Broadcasting Company, a government inquiry known as the Cameron inquiry was set up to investigate the affair. The inquiry ended with a report listing multiple mistakes by Eastern Health, and was followed by an apology by Eastern Health. Concurrently, a group of several hundred breast cancer patients treated by Eastern Health launched a class action lawsuit against it. The lawsuit has since been settled, and members of the class are now eligible for compensation.

If you underwent estrogen and progesterone receptor tests (breast cancer tests) for your breast tissue samples at the Eastern Health hospital system between 1 May 1997 to 8 August 2005, you may be eligible for the financial compensation in this Breast Cancer Class Action Lawsuit Settlement. You can check the eligibility criteria of this lawsuit settlement in the FAQ section found at www.nlbreastcancersettlement.ca.

There are two ways to get a Newfoundland & Labrador Breast Cancer Lawsuit Settlement Claim Form. You can visit nlbreastcancersettlement.ca to download the claim for or you can get the claim forms by contacting the Breast Cancer Claims Administrator whose address is available at www.nlbreastcancersettlement.ca.

To receive the financial compensation from this settlement, you have to file your claim form by August 12, 2010.

You can visit www.nlbreastcancersettlement.ca, to learn more on how to get the lawsuit settlement claim form and how to submit your claim form.

Powered by WordPress